REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
| Revenue (TTM) | $174.48M |
| Gross Profit (TTM) | $-78.42M |
| EBITDA | $-148.78M |
| Operating Margin | 27.10% |
| Return on Equity | -137.60% |
| Return on Assets | -21.20% |
| Revenue/Share (TTM) | $3.34 |
| Book Value | $1.32 |
| Price-to-Book | 8.46 |
| Price-to-Sales (TTM) | 3.38 |
| EV/Revenue | 3.269 |
| EV/EBITDA | -3.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 405.70% |
| Shares Outstanding | $66.01M |
| Float | $57.23M |
| % Insiders | 6.55% |
| % Institutions | 65.54% |
Volatility is currently expanding
REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.
Regenxbio is rated a 'risky buy' due to high volatility, regulatory setbacks, and significant near-term catalysts. RGNX faces a clinical hold on RGX-121 for Hunter Syndrome, complicating milestone payments and royalty streams, but maintains sufficient cash runway into Q4 2027. Pivotal data for the AbbVie-partnered eye disease program and BLA submission for RGX-202 in DMD represent major binary catalysts by year-end and 2027.
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.
Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome.
Regenxbio Inc. delivered a strong quarter, driven by milestone revenue, with GAAP EPS of $0.43 and revenue up 407% YoY. RGNX now holds $313 million in pro forma cash, funding operations into Q4 2027 and removing near-term financing overhang. Multiple late-stage catalysts—including RGX-202, pivotal wet AMD data, and RGX-121 resubmission—are stacked over the next 12–18 months.
REGENXBIO NASDAQ: RGNX reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an agreed path to resubmit its Hunter syndrome therapy application, and the start of a pivotal diabetic retinopathy study under its AbbVie collaboration.
REGENXBIO Inc. (RGNX) Q2 2026 Earnings Call Transcript
Regenxbio (RGNX) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $1.38 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RGNX and any ticker you trade — then tracks every position and per-strategy win rate.
